News
-
-
PRESS RELEASE
FERROSA THERAPEUTICS ANNOUNCES SEED FINANCING TO ADVANCE A FIRST-IN-CLASS BISPECIFIC ANTIBODY PROGRAM FOR ANEMIA OF INFLAMMATION
Ferrosa Therapeutics announces USD 3.5 Million seed financing to advance first-in-class bispecific antibody program for anemia of inflammation. Company targets chronic kidney disease, autoimmune disease, and cancer